

IQVIA Oncology Biomarker Monitor

Providing insights into oncology biomarker testing from laboratory directors' perspective

Oncology Biomarker Monitor (OBM), a syndicated study designed to collect key insights on the **oncology biomarker testing process** from the perspective of **diagnostic and molecular pathology laboratories**.

This study collects information on biomarker testing process itself, provides key insights that contribute to deeper understanding and enhancing the biomarker testing practice.



OBM empowers you to obtain insights on the following aspects of the biomarker testing process



Market insights and strategic planning

Understand real-world testing practices to align products with market needs and contribute to identifying gaps for improved testing platforms.



Diagnostic accuracy and reliability

Insights into common causes of delays and invalid results to enhance testing standards and reliability.



Operational efficiency

Identify common bottlenecks, turnaround testing times and provide actionable insights on laboratory testing process.



Communication and collaboration

Gain deep understanding of the level of communication between laboratories and oncologists and pathologist role in treatment decisions.



Barriers to advanced technologies

Address challenges in adopting Next-Generation Sequencing (NGS) and promote the use of advanced testing methodologies.


Study focuses on the following diseases and biomarkers which can be modified for future waves

NSCLC: EGFR, Exon20 mutation in EGFR	Prostate cancer: BRCA 1/2
Head & Neck cancer: PD-L1	Acute Myeloid Leukemia: IDH1
Colorectal cancer: KRAS, NRAS	Glioma: IDH1
Gastrointestinal cancers: HER2	Biliary tract cancer: IDH1

OBM is available across **5 countries: France, Germany, Italy, Spain, and the U.K.**

Illustrative example: OBM provides insights into biomarker test volumes and the extent to which diagnostic and molecular pathology laboratories are involved in treatment decisions.


Monthly volume of tests
(Avg number of tests)



Survey fielded **Q4 2024**
Total Respondents = **100, EU4+UK**

Communication with treating physician in oncology
(% Doctors)

Is the laboratory regularly represented in multidisciplinary meetings in oncology?



CONTACT US
oncology.dynamics@iqvia.com
Global Oncology Intelligence
iqvia.com